

1 **Supplementary Information**

2 **Roles of ErbB3 binding protein 1 (EBP1) in embryonic development and gene-silencing control**

3 Hyo Rim Ko^{1,2}, Inwoo Hwang^{1,2}, Eun-Ju Jin^{1,2}, Taegwan Yun^{1,2}, Dongryeol Ryu¹, Jong-Sun Kang^{1,2,3},
4 Kye Won Park⁴, Joo-Ho Shin^{1,2,3}, Sung-Woo Cho⁵, Kyung-Hoon Lee^{3,6}, Keqiang Ye⁷ and Jee-Yin
5 Ahn^{1,2,3*}

6 ***Correspondence should be addressed to** Jee-Yin Ahn, Department of Molecular Cell Biology,
7 Sungkyunkwan University School of Medicine, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea
8 Phone: 82-31-299-6134; Fax: 82-31-299-6139; E-mail: jeeahn@skku.edu

9

10 **This PDF file includes:**

11 Supplementary text

12 Figures S1 to S6

13 Legends for Dataset S1 to S4

14 **Materials and Methods**

15 **Animal**

16 The mouse *Ebp1* gene is located on chromosome 10 (NM_011119). The *Ebp1* gene is
17 composed of 10 exons and extends over 8.4kb. The mouse *Ebp1* knock mouse was generated in
18 collaboration with genOway (Lyon, France). *Ebp1* conditional knock-out mice were generated by
19 introduction of two *loxP* sites flanking *Ebp1* exons 6 to 10 and enable the monitoring of *Ebp1*
20 expression cells thanks to the insertion of an IRES-reporter (eGFP) cassette downstream of the stop
21 codon. Insertion of the construct selected for the neomycin marker in the targeting vector and the neo
22 cassette was flanked by *frt* sites. The construct was transfected into ES cells according to genOway's
23 standard electroporation procedures. The selected ES cells by Polymerase chain reaction (PCR) and
24 Southern Blot based screenings were injected into blastocyst.

25 To neuronal- specific deletion of *Ebp1*, homozygous mutant *Ebp1* allele (*Ebp1*^{fl^{ox}/fl^{ox}}) were
26 crossed with the Nestin-cre mice. Offspring were weaned after 4 weeks and marked by ear clipping.

27 The genomic DNA was prepared from the tail (Sigma Aldrich, Saint Louis, MO, USA) and
28 was genotyped using PCR analysis. The primer pair was designed for the detection of the cre-
29 mediated excision event.

30 All animal experimentation was reviewed and approved by the Institutional Animal Care
31 and Use Committee (IACUC) of Sungkyunkwan University School of Medicine (SUSM,
32 SKKUIACUC 17-6-4-1). All experimental procedures were carried out in accordance with the
33 regulations of the IACUC guideline of Sungkyunkwan University.

34 **Antibodies**

35 Anti-Bax (cat. 2772), and anti-Bcl2 (cat. 2870s) antibodies were acquired from Cell
36 Signaling (Danvers, MA, USA). Anti- β -actin (cat. sc-47778), anti-survivin (cat. sc-17779), anti-p21
37 (cat. sc-6246), and anti-GFP (cat. sc-9996) antibodies were acquired from Santa Cruz Biotechnology
38 (Dallas, TX, USA). Anti-*Ebp1* (cat. ab33613, ab186846), anti-BrdU (cat. ab6326), anti-DNMT1 (cat.

39 ab13537), anti-annexin V (cat. ab14196), and anti-ki67 (cat. ab8191) antibodies were obtained from
40 Abcam (Cambridge, MA, USA). Anti-PCNA was acquired from Calbiochem. Anti-H3k9me3 (cat. 07-
41 442) was obtained from Millipore (Burlington, Massachusetts, USA).

42 **Public Dataset analyses**

43 The covariation among genes (Fig. 3B and 6D) were evaluated with Pearson correlation coefficient
44 and Spearman's Rank-Order Correlation with corresponding p values (two-tailed). All raw data of
45 gene expression profile are publicly available on NCBI Gene Expression Omnibus (NCBI GEO,
46 www.ncbi.nlm.nih.gov/geo) and GeneNetwork (www.genenetwork.org). The gene expression profiles
47 were obtained from the human prefrontal cortex transcriptomes (NCBI GEO No. GSE36192), the
48 monkey (*Macaca Fascicularis*) prefrontal cortexes transcriptomes (GeneNetwork Accession No.
49 GN251), the brain transcriptomes of BXD mouse genetic reference population (GeneNetwork
50 Accession No. GN123), and the brain transcriptomes of B6D2-F2 intercross mouse population
51 (GeneNetwork Accession No. GN123). (PMID: 22433082, 20485568; 16783646; 22939713;
52 16783644; 27933521) Correlogram and interaction network were generated using RStudio (R
53 Consortium Inc, Boston, MA) as described in the previous study (PMID: 27986797).

54 **Western blotting**

55 MEF and 293t cells were washed with 15 mL of PBS and immediately added to lysis buffer
56 (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1.5 mM Na₃VO₄, 50 mM
57 sodium fluoride, 10 mM sodium pyrophosphate, 10 mM beta-glycerolphosphate, 1 mM PMSF, and
58 protease cocktail). The cell lysates were mixed with 5× SDS sample buffer, boiled, and analyzed by
59 immunoblotting. Protein levels were quantified by densitometry and normalized to actin (ImageJ
60 software).

61 **Reverse transcriptase polymerase chain reaction and qPCR**

62 Total RNA was extracted using the TAKARA miniBEST Universal RNA Extraction kit
63 (TAKARA, Japan) according to the manufacturer's instructions. The reverse transcription reaction
64 was performed using the PrimeScript 1st strand cDNA Synthesis kit (TAKARA, Japan). Data
65 normalization of transcript concentrations was performed using GAPDH.

66 **Cresyl violet staining**

67 Cresyl violet acetate crystal powder was dissolved in distilled water. The solution was
68 filtered using Whatman paper. Paraffin section slides were immersed in xylene and rehydrated by
69 passing the tissue through a series of decreasing concentrations of ethanol (100% to 70% ethanol).
70 The slides were immersed in cresyl violet staining solution for 5 min and washed in distilled water.
71 The slices were dehydrated by passing the tissue through a series of increasing ethanol concentrations
72 (70% to 100% ethanol). The final two immersions were in xylene solution. The slides were examined
73 with a microscope (Aperio ScanScope slide scanner), and their image was captured using ImageScope
74 software.

75 **FACS analysis**

76 MEF cells were fixed with 70% ethanol and store at -20°C then cells washed twice with cold
77 PBS. Cells were incubated in PBS containing 10 µg/ml RNase A and 20 µg/ml PI and transfer to
78 FACS tubes and incubate at room temperature in the dark for 30 minutes. Cells were analyzed by a
79 FACS Canto II.

80 **Immunofluorescence**

81 Mouse embryos were fixed in 4% paraformaldehyde for 15 min, permeabilized in PBS
82 containing 0.25% Triton X-100 for 1 h, and blocked in 1% BSA for 1 h. The slices were
83 immunostained using primary antibodies and the appropriate Alexa Fluor 594 goat anti-rabbit and
84 Alexa Fluor 488 goat anti-mouse secondary antibodies. Nuclei were counterstained with DAPI stain.

85 Immunostained images were acquired using a laser scanning confocal microscope (LSM 710, Carl
86 Zeiss, Germany). Fluorescent images were quantified on a pixel-by-pixel basis using a microscope
87 and Zeiss ZEN software.

88 **Global methylation assay**

89 Genomic DNA was extracted from E13.5 *Ebp1* wild-type (*Ebp1*^(+/+)), heterozygous
90 (*Ebp1*^(+/-)), and homozygous mutant (*Ebp1*^(-/-)) embryonic brain using Accuprep[®] Genomic DNA
91 Extraction kit (Cat. No. K-3032, Bioneer, Korea). Global DNA methylation levels were measured by
92 Imprint[®] Methylated DNA Quantification kit (Cat. No. MDQ1, Sigma-Aldrich, St Louis, MO, USA),
93 according to manufacturer's instruction.

94 **ChIP assay**

95 A ChIP assay was performed using a ChIP assay kit (cat. 17-259, Millipore, Temecula, CA
96 92590, USA) according to the manufacturer's instructions. In brief, a histone was crosslinked to DNA
97 by adding formaldehyde to the culture medium for 10 min at room temperature. Glycine was added
98 for 5 min to quench any unreacted formaldehyde. The cells were scraped into e-tubes and centrifuged
99 at 700 × *g* at 4°C for 1 min. The supernatant was removed, and the cell pellet was resuspended in SDS
100 lysis buffer containing 1× protease inhibitor cocktail. For immunoprecipitation, the dilution buffer,
101 chromatin, protein G agarose, and antibody were mixed and stored overnight at 4°C with rotation. The
102 protein G agarose-antibody/chromatin complex was washed by resuspending the beads in 1-mL cold
103 buffers (low salt immune complex wash buffer, high salt immune complex wash buffer, LiCl immune
104 complex wash buffer, and TE buffer in regular sequence). Elution buffer was added to the
105 antibody/agarose complex, mixed by flicking the tube gently, and incubated at room temperature for
106 15 min. To reverse crosslink of the protein/DNA complexes to free DNA, 5 M NaCl was added, and
107 the mixture was incubated at 65°C for 6 h. DNA was purified using spin columns.

108 **Embryo brain slice culture**

109 Embryo brain slice cultures were prepared from E14.5 mouse brains. The 280- μm thick brain
110 slices were obtained by vibratome sectioning (Leica VT1200, Leica Biosystems) in chilled MEMp
111 [50% (vol/vol) minimum essential medium (MEM), 25 mM HEPES, and 2 mM glutamine without
112 antibiotics, adjusted to pH 7.2–7.3 with 1 M NaOH]. The slices were transferred onto semi-porous
113 membrane inserts (Millipore, 0.4- μm pore diameter, Schwalbach, Germany). Intact slices were
114 cultured at 37°C and 5% CO₂ in maintaining medium [neurobasal medium, 2% B27, 2 mM glutamine,
115 1% penicillin/streptomycin solution, 0.5 % Glucose, and 1mg/ml gentamycin]. The medium was
116 changed every other day. The slices were infected after DIV 2 and cultured for an additional 12 days.
117 The slices were fixed with 4% PFA at DIV 14.

118 **Micro-CT**

119 E13.5 Ebp1 WT and knockout embryo samples were immersed in Lugo's solution. We used
120 the Siemens Inveon Micro-CT scanner, which is designed as an *in-vivo* system (Siemens Medical
121 Solutions, Knoxville, USA). All samples were scanned with 1.5-mm aluminium filter, using the
122 following settings: 180° total rotation and 600 rotation steps, 70 kV and 400 μA source setting, and
123 3,000 ms exposure time per step. Pixels were binned by 2, resulting in an effective pixel size or
124 resolution of approximately 19.98 μm . For each scan, the dataset was reconstructed with a
125 downsample factor of 1 using the Inveon Acquisition Workplace (IAW) software package (IAW,
126 Siemens Medical Solutions, Knoxville, TN, USA), implementing the modified Feldkamp filtered back
127 projection algorithm (Shepp-Logan filter). The reconstructed images were imported using the Inveon
128 Research Workplace (IRW) into the accompanying two-dimensional (2D) and three-dimensional (3D)
129 biomedical image analysis software package (IRW, CT Bone Visualization and Analysis, Siemens
130 Medical Solutions, Knoxville, TN, USA) for visualization and analysis.

131 **Methylation-specific PCR**

132 Genomic DNA was extracted from *Ebp1*^(+/+) and *Ebp1*^(-/-) MEF cells using the Accuprep®
 133 Genomic DNA Extraction kit (Bioneer, Daejeon, Korea). After digestion with either *MspI* or *HpaII*
 134 restriction enzymes using the EpiJET DNA Methylation Analysis kit (Thermo Scientific,
 135 Massachusetts, USA) the endogenous survivin promoter was amplified. The *HpaII* and *MspI*
 136 restriction enzymes recognized sites containing CCGG sequence. The *HpaII* restriction enzyme was
 137 unable to cut methylated cytosine, while *MspI* cut all CCGG sites. The survivin promoter on
 138 endogenous genomic DNA was amplified by using a survivin promoter-specific 5' primer
 139 (ACCGCAGCAGAAGGTACAACCTC) and a 3' primer (AAGGGCCAGTTCTTGAAG). PCR
 140 parameters were as follows: 35 cycles of 94°C for 30 s, 52°C for 30 s, and 72°C for 30 s.

141 Genotype

142 The genomic DNA was prepared from the tail (Sigma Aldrich, Saint Louis, MO,
 143 USA) and was genotyped using PCR analysis. The primer pair was designed for the detection
 144 of the cre-mediated excision event.

Genotype primer sets				
Primer name	Primer sequence	Primer product size(bp)		
		Wild-type	recombined	Cre excised
Ebp1-F	ATTGATGGAGAGAAGACGATTATCCAGAACC	3205	6298	404
Ebp1-R	ACTTGTAAGCCCAGATAGCCCTTCAGTTG			
Cre-F	GCGGTCTGGCAGTAAAACTATC	.	.	100
Cre-R	GTGAAACAGCATTGCTGTCACTT			

145

146 RNA microarray

147 The RNA microarray service was provided by Macrogen Inc.(Seoul, Republic of Korea).
 148 RNA purity and integrity were evaluated using a ND-1000 Spectrophotometer (NanoDrop,
 149 Wilmington, USA) and an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA). RNA

150 labeling and hybridization were performed according to the Agilent One-Color Microarray-Based
151 Gene Expression Analysis Protocol (Agilent Technology, V 6.5, 2010). Briefly, 100 ng of total RNA
152 from each sample was linearly amplified and labeled with Cy3-dCTP. The labeled cRNAs were
153 purified by RNAeasy Mini kit (Qiagen). The concentration and specific activity of the labeled cRNAs
154 (pmol Cy3/ μ g cRNA) were measured using NanoDrop ND-1000 (NanoDrop, Wilmington, USA).
155 Each labeled cRNA (600 ng) were fragmented by adding 5 μ L of 10 \times blocking agent and 1 μ L of 25 \times
156 fragmentation buffer and heated at 60 $^{\circ}$ C for 30 min. Finally, 25 μ L 2 \times GE hybridization buffer was
157 added to dilute the labeled cRNA. Hybridization solution (40 μ L) was dispensed into the gasket slide
158 and assembled for Agilent SurePrint G3 Mouse GE 8X60K, Microarrays (Agilent[®]). The slides were
159 incubated for 17 h at 65 $^{\circ}$ C in an Agilent hybridization oven and washed at room temperature by using
160 the Agilent One-Color Microarray-Based Gene Expression Analysis Protocol (Agilent Technology, V
161 6.5, 2010). The hybridized array was immediately scanned using the Agilent Microarray Scanner D
162 (Agilent Technologies, Inc.)

163

164 **MBD sequencing**

165 The MBD-seq service was provided by Macrogen Inc.(Seoul, Republic of Korea).
166 Methylated DNA was obtained using the MethylMiner Methylated DNA Enrichment kit (Invitrogen,
167 Carlsbad, CA, USA) according to the manufacturer's instructions. Briefly, fragmentation of 1 μ g of
168 genomic DNA was performed using adaptive focused acoustic technology (AFA; Covaris) and
169 captured by MBD proteins. The methylated DNA was eluted in high-salt elution buffer. DNA in each
170 eluted fraction was precipitated using glycogen, sodium acetate, and ethanol, and resuspended in
171 DNase-free water. The eluted DNA was used to generate libraries following the standard protocols of
172 TruSeq Nano DNA Library Prep kit (Illumina). The eluted DNA was repaired, an A was ligated to the
173 3' end, and TruSeq adapters were ligated to the fragments. Once ligation was assessed, the adapter-
174 ligated product was PCR amplified. The final purified product was quantified using qPCR according

175 to the qPCR Quantification Protocol and qualified using Agilent Technologies 4200 TapeStation
176 (Agilent technologies). We sequenced using the HiSeq™ 2500 platform (Illumina). Paired-end
177 sequencing reads (101 bp) generated from MBD sequencing were verified using FastQC (version
178 0.10.0). Before starting the analysis, Trimmomatic (version 0.32) was used to remove any adapter
179 sequences and bases with base qualities lower than 3 from the end reads. Using the sliding window
180 trim method, bases that did not qualify for window size = 4 and mean quality = 15 were removed.
181 Thereafter, reads with a minimum length of 36 bp were removed to produce clean data. The cleaned
182 reads were aligned to the human genome (UCSC mm10) using Bowtie (version 1.1.2 parameter set -n
183 2 -m 1 -X 600), allowing up to 2 nucleotide mismatches to the reference genome per seed and
184 returning only uniquely mapped reads. Mapped data (SAM file format) were performed sorting and
185 indexing using SAMtools (version 0.1.19). PCR duplicates were removed using Picard Mark
186 Duplicates (version 1.118). The analysis of the MBD data was performed using the MEDIPS package
187 (version 1.16.0). For each sample, the aligned reads were extended in the sequencing direction to a
188 length of 300 nt. The sequencing read coverage of the extended reads was calculated at genome-wide
189 250 bp window size. Subsequently, the resulting coverage profiles (read count, RPKM, and RMS) at
190 each genomic bin were calculated. Each DMR was annotated using the table browser function of the
191 UCSC genome browser. Annotation included gene structures, transcripts, promoter regions (defined
192 as -2 kb upstream of the transcription start site), exons, introns, and CpG islands.

193

194 **ChIP sequencing**

195 The ChIP-seq service was provided by MacroGen Inc.(Seoul, Republic of Korea). ChIPed DNA was
196 quantified using Quant-IT PicoGreen (Invitrogen) and qualified using the Agilent High Sensitivity
197 DNA kit on an Agilent 2100 Bioanalyzer (Agilent Technologies). The sequencing libraries were
198 prepared according to TruSeq ChIP Sample Preparation kit manufacturer's instructions (Illumina, Inc.,
199 San Diego, CA, USA). Briefly, 10 ng of ChIPed DNA was end-repaired to create 5'-phosphorylated,


200 blunt-ended dsDNA molecules. Following end-repair, DNA was size-selected using a bead-based
201 method. These DNA fragments went through the addition of a single A base and ligation of the
202 TruSeq indexing adapters. The products were purified and enriched with PCR to create the final DNA
203 library. The libraries were quantified using qPCR according to the qPCR Quantification Protocol
204 (KAPA Library Quantification kits for Illumina Sequencing platforms) and qualified using the
205 TapeStation D1000 ScreenTape (Agilent Technologies, Waldbronn, Germany). Indexed libraries were
206 sequenced using the HiSeq2500 platform (Illumina, San Diego, USA by the Macrogen Incorporated).
207 Library preparation was carried out according to the TruSeq ChIPSeq method (Illumina). Paired-end
208 sequencing reads (101 bp) generated using a HiSeq4000 instrument were verified for sequence quality
209 using FastQC (version 0.10.0). Before starting the analysis, Trimmomatic (version 0.32) was used to
210 remove adapter sequences and bases with base qualities lower than 3 from the end reads. Using a
211 sliding window trim method, bases that did not qualify for window size = 4 and mean quality = 15
212 were removed. Thereafter, reads with a minimum length of 36 bp were removed to produce clean data.

213 **Primer list**

Reverse transcriptase polymerase chain reaction and qPCR			
GENE	Primer sequence	GENE	Primer sequence
Bcl2	F: AAG CTG TCA CAG AGG GGC TA	Kdm3a	F:CAGGTTGGAGCTGGAGACT
Bcl2	R: GAC GGT AGC GAC GAG AGA AG	Kdm3a	R: TCT GCA GTT CAG GAG TGG TG
Bax	F: TGC AGA GGA TGA TTG CTG AC	Prdm5	F: AAG GGC TTT GCT CAC AGA AA
Bax	R: GAT CAG CTC GGG CAC TTT AG	Prdm5	R: GCC TTA TTG CAC AGC TCA CA
Vegf A	F: CAG GCT GCT GTA ACG ATG AA	Dnmt1	F: ACG GAA ACC CAA GGA AGA GT
Vegf A	R: GCA TTC ACA TCT GCT GTG CT	Dnmt1	R: TTC CGG TCT TGC TTC TCT GT
Gata 4	F: GCA GCA GCA GTG AAG AGA TG	Suv39H1	F: CAG GTA GCT GTT GGC TGT GA
Gata 4	R: GCG ATG TCT GAG TGA CAG GA	Suv39H1	R: AGT GCG GAA GAT GCA GAG AT
Cd31	F: TGC AGG AGT CCT TCT CCA CT	Dot1	F: TGG CAA GCC TGT CTC CTA CT
Cd31	R: ACG GTT TGA TTC CAC TTT GC	Dot1	R: TGG CAG CAC TCA TTT TCT TG
Sox18	F: AAC AAA ATC CGG ATC TGC AC	Ezh	F: ATC TGA GAA GGG ACC GGT TT
Sox18	R: GGT AGG CTC CAG TTG CTC TG	Ezh	R: TCA GGG TCT TTA ACG GGA TG
Sox17	F: CTC GGG GAT GTA AAG GTG AA	Survivin	F: ATC GCC ACC TTC AAG AAC TG
Sox17	R: GCT TCT CTG CCA AGG TCA AC	Survivin	R: CAG GGG AGT GCT TTC TAT GC
Endoglin	F: CTT CCA AGG ACA GCC AAG AG	Sox18	F: AAA GAA TTC ATG CAG AGA TCG CCG CCC
Endoglin	R: GTG GTT GCC ATT CAA GTG TG	Sox18	R: AAA GGA TCC CTC CGC ACC CAG AGT GGG
Ebp1	F: AGA GCA TTT GAA GAT GAG	Ebp1	R: TCAGTCCCCAGCTTCATT
ChIP assay			
Primer	Primer sequence	Primer	Primer sequence
Dnmt1 (-500F)	CTG GCT TTT GCA TTC TGA	Dnmt1 (+200 R)	CAA ACG CTG CCC CGC GCA
Survivin (-966F)	ACGTGACAAAACCCCTCTTG	Survivin (-365R)	CAG GTT CTT CCT GCC TCA AG
Survivin (-364F)	CAG AGC ACA TGG GAC TTG CAG	Survivin (-115R)	TGC CTT CTG GGA GTG GAC
Survivin (-132F)	GTC CAC TCC CAG AAG GCA	Survivin (+79R)	AAG GGC CAG TTC TTG AAG

214

215




217

218 **Fig. S1 Genetic ablation of *Ebp1* in mice.**

219 (A) Generation of *Ebp1* knockout mice. Selected ES clones by PCR and Southern blot analysis for
 220 blastocyst injection. (B) Generation of heterozygous *Ebp1* constitutive knockout mice. (C and D)
 221 *Ebp1* levels were checked in E13.5 mouse brains with the indicated genotypes using RT-PCR (C) and
 222 immunoblotting (D). The total RNA concentration was determined to GAPDH mRNA, and an equal
 223 amount of total proteins were detected using anti-Actin antibody. (E) *Ebp1*^(-/-) mice exhibit embryonic


224 lethality (>468 pups analyzed). The ratio between wild-type and heterozygous mice was
225 approximately 1:1.7 (36.8% and 63.2%, respectively). (F) Body weights in *Ebp1* wild-type and hetero
226 mice. Data shown are body weight over 6 weeks. (G) Calculation of the percentage of embryo
227 genotypes at each time point. (H) Gross morphology of *Ebp1* wild-type (*Ebp1*^(+/+)), hetero (*Ebp1*^(+/-)),
228 and knockout (*Ebp1*^(-/-)) mouse littermate from E11.5 to E15.5. Scale bar 500 μ m. (I) Body area of
229 embryonic *Ebp1* wild-type (*Ebp1*^(+/+)), hetero (*Ebp1*^(+/-)), and knockout (*Ebp1*^(-/-)) mouse from E11.5
230 to E13.5. (J) Whole-mount CD31 staining of E11.5 of *Ebp1*^(+/+) and *Ebp1*^(-/-) brain reveals comparable
231 microvascular networks (left). Black arrows indicate the branching points and red arrows indicate
232 blood vessels. Scale bar 100 μ m. Quantification of branching point measurements from three
233 independent experiments is shown on the right. Data are shown as mean \pm SEM; **** $p < 0.0001$
234 versus the *Ebp1*^(+/+). (K) Whole-mount CD31 staining of E11.5 of *Ebp1*^(+/+) and *Ebp1*^(-/-). The
235 enlargement of the brain reveals microvascular networks. Scale bar 500 μ m, Scale bar 50 μ m
236 (Magnification). (L) Quantitative RT-PCR analysis of angiogenesis-related genes from E13.5
237 *Ebp1*^(+/+) or *Ebp1*^(-/-) Yolk sacs. The mRNA levels of these genes were normalized to that of GAPDH.
238 The relative fold changes were quantified and shown in the bar graphs.



239

240 **Fig. S2 Generation of [Nestin-Cre; *Ebp1*^{lox/lox}] mice.**

241 (A) The entorhinal cortex-hippocampus (EH) organotypic slices from P7 mice were cultured for 10
 242 days and used for immunostaining. Immunofluorescence images were obtained after double-
 243 immunostaining using anti-EBP1 (red) and NeuN (green). DAPI was used for nuclear staining. Scale
 244 bar 50 μ m. (B) Schematic representation of the targeting strategy for the generation of Ebp1
 245 conditional knockout mice (left). The genomic DNA of the heterozygous conditional knockout tested
 246 was compared to wild-type DNA by Southern blot analysis (right). (C) Mouse brains with indicated
 247 genotypes were checked EBP1 levels by immunoblotting. (D) mRNA levels of Ebp1 were detected
 248 using RT-PCR from E10.5 to P7. The total RNA concentration was determined to GAPDH mRNA. (E
 249 and F) The paraffin-embedded section of the genotypes indicated was immunostained with anti-EBP1
 250 antibody at E18.5, and postnatal 7 days (F).




252

253 **Fig. S3 Effect of *Ebp1* loss on apoptosis and cell proliferation.**

254 (A) Paraffin section with indicated genotypes was stained with anti-BrdU antibody (brown). Scale bar
 255 1 mm. (B) Paraffin section was stained with anti-PCNA antibody. Scale bar 1 mm, scale bar 100 μ m
 256 (Enlargement). Quantification of PCNA positive cells is shown as a bar graph. Images shown here are
 257 representative of at least three independent experiments, and each value represents the mean \pm SEM
 258 of triplicate measurements. **** $p < 0.00005$ versus wild-type. (C) MEF cells were stained with
 259 annexin V (red) and DAPI (blue). The bar graph shows annexin V fluorescence intensity. Data
 260 represent the mean \pm SEM of three independent experiments. ** $p < 0.005$ versus *Ebp1* wild-type. (D)
 261 RNA and proteins were isolated from MEF cells (passage 2) of the genotypes indicated. The mRNA
 262 levels and protein levels of Bax and Bcl2 were determined by RT-PCR and immunoblot. The total


263 RNA concentration was determined to GAPDH mRNA, and an equal amount of total proteins were
264 detected using anti-actin antibody. (E) Cell cycle-related protein expression was checked in MEF cells
265 (passage 2) by immunoblotting. Actin served as the loading control. (F) The representative image
266 shows *Ebp1*^(+/+) and *Ebp1*^(-/-) MEF cells at passage 2 and passage 6. Scale bar 100 μm.



267

268 Fig. S4 Differential DNA methylation region in *Ebp1*^(+/+) and *Ebp1*^(-/-) mice.

269 (A) Microarray analysis was conducted by using mouse brain and displayed genes whose expression
270 was ≥ 1.5 or 2.0. fold up- or down-regulated between *Ebp1*^(+/+) and *Ebp1*^(-/-) groups. (B) Heatmap is
271 a representation of microarray data related to methylation between *Ebp1*^(+/+) and *Ebp1*^(-/-) groups. The
272 values of the data are represented in color. Black indicates high expression, and red indicates low
273 expression. (C) The heatmap shows the level of H3K9 trimethylation related genes between *Ebp1*^(+/+)
274 and *Ebp1*^(-/-) groups. Black indicates high expression, and red indicates low expression. (D) MEF cell
275 (passage 2) lysates were subjected to western blot. Methylation at histone H3 lysine 9 tri-methylation
276 (H3K9me3) was detected anti-H3K9me3 antibody. Amount of total proteins were detected using anti-
277 Actin antibody. (E) 293T cells were transfected with scramble RNA or si-Ebp1 RNA. Twenty-four
278 hours after transfection, cell lysates were performed western blot. The indicated antibody detected
279 protein levels. (F) MBD sequencing was performed using *Ebp1*^(+/+) and *Ebp1*^(-/-) embryonic brain
280 (E15.5). The heatmap shows methylated DNA distribution in CGI promoter (left) and non-CGI
281 promoter region (right) in *Ebp1*^(-/-) / *Ebp1*^(+/+) mouse. Black represents high methylation level, and red
282 indicates low methylation level. (G) Functional GO-term annotation of hyper-methylated CGI
283 promoter region in *Ebp1*^(-/-). Gene lists derived from MBD-seq analysis of *Ebp1*^(-/-) / *Ebp1*^(+/+) mouse
284 were applied to DAVID to identify functional ontological groups. The heatmaps are derived from the
285 report generated by DAVID and are an annotated-term-focused view that lists annotated genes and
286 their GO-term. Black color represents gene-term associations not reported yet in DAVID and green
287 color represents gene-term associations positively reported in DAVID.




288

289 **Fig. S5 Analysis of EBP1-ChIP-seq data.**

290 (A and B) ChIP assay was performed with anti-EBP1 antibody using mouse embryo fibroblast
 291 (passage 2). Coverage plot shows EBP1 chromosomal-binding site over the entire chromosome (A)
 292 and genomic distribution of EBP1-binding sites visualized by ChIP seeker (B). See *SI Appendix*
 293 *Dataset 2*. (C) MEF cells were used for ChIP-seq analysis with the anti-EBP1 antibody. Integrative
 294 Genomics Viewer (IGV) track view of ChIP seq density profile for EBP1. (D) Functional GO-term
 295 annotation of ChIP-seq data analysis. Gene lists derived from ChIP-seq analysis of *Ebp1* were applied
 296 to DAVID to identify functional ontological groups. Black color represents gene-term associations not
 297 reported yet in DAVID and green color represents gene-term association positively reported in

298 DAVID. (E) MEF with the indicated genotypes was transfected with control or GFP-Ebp1. DNMT1
299 expression levels were determined by immunoblotting. HSP70 served as the loading control.



300

301 **Fig. S6 EBP1 impairs DNMT1 mediated promoter methylation.**

302 (A and B) RNA and proteins were isolated from MEF cells (passage 2) with the indicated genotypes.

303 The mRNA levels (A) and protein levels (B) of Survivin and Ebp1 were determined by RT-PCR and

304 immunoblot. The total RNA concentration was determined to GAPDH mRNA, and an equal amount

305 of total proteins were detected using anti-actin antibody. (C) MBD sequencing was performed in

306 E15.5 *Ebp1*^(+/+) and *Ebp1*^(-/-) embryonic brain. The bar graph shows the methylation probability of the

307 Dnmt1 target genes CGI promoter region. See *SI Appendix* Dataset S3. (D) RNA was isolated from

308 the brain with the indicated genotypes. The mRNA levels of *Kcna2* and *Klf13* were determined by

309 RT-PCR. The total RNA concentration was determined to GAPDH mRNA. (E) Genomic DNA

310 (gDNA) was extracted from *Ebp1*^(+/+) and *Ebp1*^(-/-) embryonic brain. The extracted gDNA was

311 subjected to methylation-specific PCR (MSP). U: undigested DNA, H: digested with Hpa1, M:

312 digested with MSP1.

313

314 **Dataset S1. Correlation matrices showing Pearson's r between *Ebp1* and the other genes.**

315 Correlation matrices are shown Pearson's r between *Ebp1* and the other genes (*i.e.* *Dnmt1*, *Suv39h1*,
316 *Ezh2*, *Prdm5*, and *Dot1*) in the brain of the monkey (*Macaca Fascicularis*, n = 147), BXD mouse
317 genetic reference population (n = 50) and B6D2-F2 intercross mouse population (n = 56), and in the
318 hypothalamus of Mouse diversity panel (n = 17), with the depth of shading of correlogram according
319 to the magnitude of the correlation and positive and negative correlations represented in blue and red,
320 respectively.

321 **Dataset S2. EBP1 ChIP-seq data.**

322 ChIP assay was performed with anti-EBP1 antibody using mouse embryo fibroblast (passage 2).

323 **Dataset S3. EBP1 MBD-seq data.**

324 MBD sequencing was performed using *Ebp1*^(+/+) and *Ebp1*^(-/-) embryonic brain (E15.5).

325 **Dataset S4. Scatterplots showing the negative correlation between *Ebp1* and *Dnmt1* expression.**

326 Scatterplots are shown the negative correlation between *Ebp1* and *Dnmt1* expression in the brain of
327 human (n = 147; Pearson's r = -0.46, p < 0.0001; Spearman's rho = -0.38, p < 0.0001), monkey
328 (*Macaca Fascicularis*, n = 64; Pearson's r = -0.43, p < 0.0001; Spearman's rho = -0.47, p < 0.0001),
329 BXD mouse genetic reference population (n = 50; Pearson's r = -0.30, p < 0.033; Spearman's rho = -
330 0.31, p < 0.026), and B6D2-F2 intercross mouse population (n = 56; Pearson's r = -0.33, p < 0.012;
331 Spearman's rho = -0.28, p < 0.034).